Abstract The efficacy of PET image-guided immune checkpoint inhibitor-based therapy in hepatocellular carcinoma (HCC) management is limited by the lack of direct monitoring of therapeutic response. A key challenge is the mismatch between the therapeutic pathway and the imaging target, which hinders the accurate assessment of treatment outcomes.
Dalong Ni
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Dalong
Contact Dalong, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack